Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLC

March 26th 2021

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.

Dr. Bazhenova on a Correlative Analysis of the KRYSTAL-1 Trial in Advanced NSCLC

March 26th 2021

Lyudmila A. Bazhenova, MD, discusses the results of a preliminary exploratory correlative analysis of the phase 1/2 KRYSTAL-1 trial in advanced non–small cell lung cancer.

Chemotherapy Plus Immunotherapy Shows No Benefit Following Osimertinib in EGFR+ NSCLC

March 26th 2021

Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.

Prior Immunotherapy or Osimertinib Negatively Impacts Outcomes With Subsequent Atezolizumab in NSCLC

March 26th 2021

Previous exposure to immune checkpoint inhibitors or osimertinib has been linked with poor outcomes in patients with non–small cell lung cancer who were receiving a subsequent atezolizumab-containing regimen.

AMG 757 Shows Early Efficacy, Safety in Small Cell Lung Cancer

March 26th 2021

The half-life extended, DLL3-targeting bispecific T-cell engager AMG 757 demonstrated early signals of efficacy and a favorable safety profile in patients with small cell lung cancer.

EU Panel Recommends Atezolizumab for Frontline PD-L1–High Metastatic NSCLC

March 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of atezolizumab for use as a frontline treatment in adult patients with metastatic non–small cell lung cancer whose tumors have a high PD-L1 expression and no EGFR or ALK aberrations.

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

March 25th 2021

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

Dr. Garassino on the Rationale for the PACIFIC-6 Trial in NSCLC

March 25th 2021

Marina Chiara Garassino, MD, discusses the rationale for the phase 2 PACIFIC-6 trial in non–small cell lung cancer.

Camrelizumab Plus Chemo Prolongs PFS in Advanced Squamous NSCLC

March 25th 2021

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

FASN Inhibitor AZ12756122 Reduces Resistance Properties in EGFR TKI–Resistant, EGFR-Mutant NSCLC Models

March 25th 2021

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

Nivolumab/Ipilimumab Plus Short-Course Chemo Improves OS Regardless of TMB Status in Advanced NSCLC

March 25th 2021

The frontline combination of nivolumab and ipilimumab plus 2 cycles of chemotherapy demonstrated an improvement in overall survival vs chemotherapy alone in patients with advanced non–small cell lung cancer regardless of tumor mutational burden status in the tissue or blood.

Standard of Care for ES-SCLC

March 25th 2021

Experts in thoracic oncology review data from the IMpower133 and CASPIAN trials as well as the use of chemotherapy with PD-L1 inhibitors for treatment-naïve ES-SCLC in clinical practice.

Staging for Small-Cell Lung Cancer

March 25th 2021

Insights on the differences between limited-stage and extensive-stage small-cell lung cancer and recent progress made with combination chemotherapy plus immunotherapy.

FDA Grants 2 Breakthrough Device Designations to Signatera MRD Test

March 24th 2021

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer

March 24th 2021

Wade T. Iams, MD, discusses the emergence of TKIs and antibody-drug conjugates in HER2-mutant lung cancer.

Dr. Boyle on Approaching Biomarker Testing in Lung Cancer

March 24th 2021

Theresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.

Portnoy Previews Immunotherapy Breakthroughs Shaking Up Frontline SCLC Paradigm

March 24th 2021

David C. Portnoy, MD, FACP, discusses ongoing studies examining immunotherapy and what is needed to move the needle forward in SCLC.

Dr. Longshore on Comprehensive Vs Single-Gene Molecular Testing in Lung Cancer

March 22nd 2021

John Longshore, PhD, FACMG, discusses selecting between comprehensive vs single-gene molecular testing in lung cancer.

Atezolizumab Improves DFS Over BSC in PD-L1+ Resectable, Early-Stage NSCLC

March 22nd 2021

The PD-L1 inhibitor atezolizumab was found to improve disease-free survival over best supportive care when used as an adjuvant treatment in patients with PD-L1–positive, stage II-IIIA non–small cell lung cancer, meeting the primary end point of the phase 3 IMpower010 trial.

Dr. Hanna on Approaching Biomarker Testing in Lung Cancer

March 18th 2021

Nasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.